New target found for cancers resistant to Iressa and Herceptin
A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors.
Sep 4, 2012
0
0